Sat, Dec 27, 2014, 9:28 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

YM BioSciences, Inc. Ordinary S Message Board

  • epritske epritske Nov 19, 2012 11:59 AM Flag

    We Are in the Eight Inning With Partnership

    Based on price action, and my discussion with James Smith, I believe we are in eight inning of partnership news. It looks like there is a big pharma and small company with merger interest. The stock price action that has happened looks to be deliberate. I know many here do not believe in stock price manipulation, but I strongly belive this to be accurate. Hopefully, the long wait will provide a great negotiation deal with partner for all investors here that have been waiting patiently...

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You and me both! I'm not pointing fingers at any one group, but a large investor having a strategic bias would certainly not be shocking. I've seen this in other deals. Just before Adolor was acquired their stock fell so much and no one could figure it out. Cubist snapped them up for an awesome premium. It was trading at like 1.90 and they were taken out at 4.25 with another 4.50 in contingent payment rights pending certain milestones being hit. You could almost see that same situation playing out here. It would be hard to turn down. There are only so many comps out there for deals so Adolor is highly my opinion anyway.

      • 1 Reply to investormdpart2
      • They may or may not be close to a partnership - frankly, i think it's very hard to say, and i don't think the price action necessarily means a thing because the market has been very weak since the presidential election and likely remain that way - and will probably go down further (Goldman predicts down an additional 7-8%) until and unless there is a budget resolution. Below is what Merrill published about YMI on Nov 9th - i'm still bearish but what do i know.

        Partnering, Phase 3 start – upcoming potential catalysts
        YMI today reported FY1Q13 financial results generally in line with our model and
        we revised our EPS estimates accordingly. YMI continues to work through
        discussions with potential partners before it embarks on a Phase 3 study of its key
        pipeline drug CYT387, a Jak1/2 inhibitor for the treatment of myelofibrosis. YMI
        will not commit to a particular development strategy for CYT387 (eg vs. placebo
        or INCY’s Jakafi) until a partnership decision is made. In the absence of a
        partnership, YMI believes it can ramp up a Phase 3 fairly quickly, as there are no
        additional regulatory discussions or additional testing required. Final 9-month data
        from the ongoing Phase 1/2 study of CYT387 will be presented at the ASH
        meeting in December.

    • LoL

      And you still believe every word they tell you after you've been told that there would be no dilution?


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.